

Second Quarter FY 2025 Results

November 7th, 2024



Safe Harbor Disclosure

This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, organic revenue growth, adjusted diluted EPS, and free cash flow; the Company's ability to execute on its brand-building strategy and to drive free cash flow and maximize shareholder value; the Company's expected growth, including with respect to international sales; stability of the Company's gross margin; the impact and timing of supply chain challenges; and the Company's capital allocation strategy and optionality, including its pursuit of M&A, share buybacks and debt reduction. Words such as "continue," "expect," "remain," "positioned," "proven," "outlook," "will," "may," "should," "could," "would," and similar expressions identify forward-looking statements. Such forward-looking statements represent the Company's expectations and beliefs and involve a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include, among others, the ability of the Company's manufacturing operations and third party manufacturers and logistics providers and suppliers to meet demand for its products and to avoid inflationary cost increases and disruption as a result of labor shortages; the impact of economic and business conditions; consumer trends; competitive pressures; the impact of the Company's advertising and promotional and new product development initiatives; customer inventory management initiatives; the ability to pass along rising costs to customers without impacting sales; fluctuating foreign exchange rates; and other risks set forth in Part I, Item 1A. Risk Factors in the Company's Annual Report on Form 10-K for the year ended March 31, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation. Except to the extent required by applicable law, the Company undertakes no obligation to update any forward-looking statement contained in this presentation, whether as a result of new information, future events, or otherwise.

All adjusted GAAP numbers presented are footnoted and reconciled to their closest GAAP measurement in the attached reconciliation schedule or in our November 7, 2024 earnings release in the "About Non-GAAP Financial Measures" section.



- I. Performance Update
- II. Financial Overview
- III. FY 25 Outlook





I. Performance Update




Strong Results in Second Quarter FY 25

Quarterly Revenue of \$283.8 million, ahead of expectations Q2 FY 25 Sales Outperformance highlighted by strong International growth Drivers Continue to execute proven brand-building strategy Gross Margin performance stable **Superior Earnings** Adjusted Diluted EPS⁽²⁾ up slightly versus prior year and FCF Strong financial profile and resulting Free Cash Flow⁽²⁾ generation Leverage of 2.7x⁽³⁾ continues to enable capital allocation optionality **Disciplined Capital** Further debt reduction and opportunistic share repurchases in 2Q Allocation M&A, share buybacks, and debt reduction remain optimal capital allocation levers



Canada: Time-Tested Branded Leadership Driving Growth (+)



Brand Building Strategy At Work Enabling Robust Long-Term Growth



SECOND QUARTER FY 25 RESULTS


* in constant CAD

II. Financial Overview



∠i≡ \$≣

Second Quarter and 1H FY 25 Performance Highlights



Revenues of \$283.8 million, down 0.8% versus record prior year excluding FX

EBITDA⁽²⁾ of \$91.9 million down 4.0% versus prior year due mainly to timing of costs

Diluted EPS of \$1.09 up 1.7% versus prior year

PrestigeConsumer HEALTHCARE

Dollar values in millions, except per share data

FY 25 Second Quarter and 1H Consolidated Financial Summary

	3 Mo	onths E	nded	6 Months Ended							
	Q2 FY 25	Q2 FY 24	% Chg	1H FY 25	1H FY 24	% Chg					
Total Revenues	\$ 283.8	\$ 286.3	(0.9%)	\$ 550.9	\$ 565.6	(2.6%)					
Gross Margin % Margin	157.4 55.5%	160.0 55.9%	(1.6%)	303.4 55.1%	314.7 55.6%	(3.6%)					
A&M % Total Revenues	41.4 14.6%	40.1 <i>14.0%</i>	3.3%	80.8 14.7%	76.3 13.5%	5.8%					
G&A % Total Revenues	26.1 9.2%	26.0 9.1%	0.3%	55.0 10.0%	53.7 9.5%	2.4%					
D&A	5.6	5.7	(1.8%)	11.3	11.2	0.3%					
Operating Income % Margin	\$ 84.3 29.7%	\$ 88.3 30.8%	(4.4%)	\$ 156.4 28.4%	\$ 173.4 30.7%	(9.8%)					
Adj. Diluted Earnings Per Share ⁽²⁾	\$ 1.09	\$ 1.07	1.7%	\$ 1.98	\$ 2.13	(6.9%)					
EBITDA ⁽²⁾ % Margin	\$ 91.9 32.4%	\$ 95.7 33.4%	(4.0%)	\$ 171.5 <i>31.1%</i>	\$ 189.6 33.5%	(9.5%)					

1H Comments

Organic Revenue⁽¹⁾ down 2.5% vs. prior year

- *Clear Eyes* sales similar to expectations
- International segment up 4.8% excluding currency
- Women's Health category performance improving sequentially
- Double-digit growth in eCommerce

Gross Margin of 55.1% as expected, owing to higher air freight

A&M of 14.7% of Revenue, as expected

G&A of 10.0% of Revenue, as expected

Adj. Diluted EPS⁽²⁾ down vs. prior year due to timing of costs and anticipated revenue pressures from supply

Dollar values in millions, except per share data; D&A excludes COGS D&A




Industry Leading Free Cash Flow Trends

Free Cash Flow ⁽²⁾	Comments
Q2 FY 25 Q2 FY 24 1H FY 25 1H	 Total 1H Free Cash Flow⁽²⁾ of \$121.4 million up 14% vs. prior year
\$121.4	 Maintaining full-year free cash flow outlook⁽⁵⁾ of \$240 million or more
\$106.	 Strong business attributes continue to drive Free Cash Flow
\$67.8 \$59.5	 Net Debt at September 30 of \$1.0 billion⁽²⁾; leverage ratio⁽³⁾ of 2.7x at end of Q2
	 Repurchased approximately 566,000 shares in 1H for approximately \$38 million
	 Low leverage and consistent business performances enables further strategic capital deployment flexibility in
Free Cash Flow Free Cash Flow	w second half
Dollar values in millions	
PrestigeConsumer HEALTHCARE	SECOND QUARTER FY 25 RESULTS 1

III. FY 25 Outlook



FY 25 Outlook Unchanged









Appendix

- (1) Organic Revenue is a Non-GAAP financial measure and is reconciled to the most closely related GAAP financial measures in the attached Reconciliation Schedules and / or our earnings release dated November 7, 2024 in the "About Non-GAAP Financial Measures" section.
- (2) EBITDA & EBITDA Margin, Adjusted Diluted EPS, Free Cash Flow, and Net Debt are Non-GAAP financial measures and are reconciled to their most closely related GAAP financial measures in the attached Reconciliation Schedules and / or in our earnings release dated November 7, 2024 in the "About Non GAAP Financial Measures" section.
- (3) Leverage ratio reflects covenant defined Net Debt / EBITDA.
- (4) Adjusted Diluted EPS for FY 25 is a projected Non-GAAP financial measure, is reconciled to projected GAAP Diluted EPS in the attached Reconciliation Schedules and/or in our earnings release dated November 7, 2024 in the "About Non-GAAP Financial Measures" section and is calculated based on projected GAAP Diluted EPS adjusted for certain discrete tax items.
- (5) Free Cash Flow for FY 25 is a projected Non-GAAP financial measure, is reconciled to projected GAAP Net Cash Provided by Operating Activities in the attached Reconciliation Schedules and / or in our earnings release dated November 7, 2024 in the "About Non-GAAP Financial Measures" section and is calculated based on projected Net Cash Provided by Operating Activities less projected capital expenditures.



Reconciliation Schedules

Organic Revenue Change

	Т	hree Months End	otember 30,	Six Months Ended September 30,				
		2024		2023	2024		2023	
(In Thousands)								
GAAP Total Revenues	\$	283,785	\$	286,316	\$ 550,927	\$	565,625	
Revenue Change		(0.9%)			 (2.6%)			
Adjustments:								
Impact of foreign currency exchange rates		-		(165)	-		(334)	
Total adjustments	\$	-	\$	(165)	\$ -	\$	(334)	
Non-GAAP Organic Revenues	\$	283,785	\$	286,151	\$ 550,927	\$	565,291	
Non-GAAP Organic Revenue Change		(0.8%)			(2.5%)			

EBITDA Margin

	1	Three Months End	ded Sep	tember 30,	Six Months Ended September 30,				
		2024		2023		2024	2023		
<u>(In Thousands)</u>									
GAAP Net Income	\$	54,377	\$	53,559	\$	103,445	\$	106,835	
Interest expense, net		12,281		17,606		25,418		35,325	
Provision for income taxes		17,286		16,856		26,631		32,293	
Depreciation and amortization		7,929		7,643		16,053		15,186	
Non-GAAP EBITDA	\$	91,873	\$	95,664	\$	171,547	\$	189,639	
Non-GAAP EBITDA Margin		32.4%		33.4%		31.1%		33.5%	



Reconciliation Schedules (Continued)

Adjusted Diluted EPS

		Three Months Ended September 30,							:	Six Mo	onths Ende	led September 30,					
		2024				20)23			20	24		2023				
	Ne	t Income	Dilu	ted EPS	Ne	t Income	Dilu	ted EPS	Ne	t Income	Dilu	ted EPS	Ne	et Income	Dilu	ted EPS	
(In Thousands, except per share data)																	
GAAP Net Income and Diluted EPS	\$	54,377	\$	1.09	\$	53,559	\$	1.07	\$	103,445	\$	2.06	\$	106,835	\$	2.13	
Adjustments:									_								
Normalized tax rate adjustment ^(a)		-		-		-		-		(4,030)		(0.08)		-		-	
Total Adjustments	_	-		-	_	-		-		(4,030)		(0.08)		-		-	
Non-GAAP Adjusted Net Income and Adjusted Diluted EPS	\$	54,377	\$	1.09	\$	53,559	\$	1.07	\$	99,415	\$	1.98	\$	106,835	\$	2.13	
(a) Income tax adjustment to adjust for discrete income tax items																	

(a) Income tax adjustment to adjust for discrete income tax items.

Free Cash Flow

	Th	ree Months End	led Sep	tember 30,	:	Six Months Ended September 30,				
		2024		2023	2024			2023		
(In Thousands)										
GAAP Net Income	\$	54,377	\$	53,559	\$	103,445	\$	106,835		
Adjustments:										
Adjustments to reconcile net income to net										
cash provided by operating activities as shown in										
the Statement of Cash Flows		16,045		19,862		30,371		38,050		
Changes in operating assets and liabilities as shown in the										
Statement of Cash Flows		(622)		(10,961)		(9,240)		(34,338)		
Total adjustments		15,423		8,901		21,131		3,712		
GAAP Net cash provided by operating activities		69,800		62,460		124,576		110,547		
Purchase of property and equipment		(2,027)		(2,934)		(3,179)		(4,411)		
Non-GAAP Free Cash Flow	\$	67,773	\$	59,526	\$	121,397	\$	106,136		



Reconciliation Schedules (Continued)

Projected Adjusted Diluted EPS

	L	ow	High
Projected FY'25 GAAP Diluted EPS	\$	4.48	\$ 4.54
Adjustments:			
Normalized Tax Rate Adjustment ^(a)		(0.08)	 (0.08)
Total Adjustments		(0.08)	(0.08)
Projected FY'25 Non-GAAP Adjusted Diluted EPS	\$	4.40	\$ 4.46

(a) Income tax adjustment to adjust for discrete income tax items

Projected Free Cash Flow

<u>(In millions)</u>	
Projected FY'25 GAAP Net cash provided by operating activities	\$ 250
Additions to property and equipment for cash	 (10)
Projected FY'25 Non-GAAP Free Cash Flow	\$ 240

